Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan + lenvatinib versus cabozantinib after prior anti-PD-1/L1 therapy in advanced clear cell renal cell carcinoma
NL-OMON52328Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Belzutifan + lenvatinib with Cabozantinib (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2021; status: completed.
02
Drugs
belzutifanlenvatinibcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON52328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52328.